

Quality for Biologics

Part Two: Characterization and Analytical Methods

Physicochemical characterisation, bioassays, formulation and specifications

Table of Contents

Chapter 4

Introduction: Characterization of the Biologic Product

Thomas Schreitmuller PhD, *Head of Analytical R&D and Quality Control Biotech Products, F. Hoffmann-La Roche, Switzerland*

1. The historical perspective
2. The current status
3. The perspective
4. Some examples
5. Conclusions

Chapter 5

Technology Selection for Physicochemical Characterisation

Dr John O'Hara, *Characterisation Group Leader, Analytical Research and Development, UCB-Celltech, UK*

Dr Andy Hooker, *Senior Director of Analytical Research and Development, UCB-Celltech, UK*

1. Introduction
2. Well characterised biologicals and specified biotechnology products
3. Heterogeneity of biopharmaceutical products and physicochemical testing
4. Evolution in physicochemical characterisation during development
5. Physicochemical characterisation and bioactivity
6. Physicochemical lot release testing
7. Case studies

Chapter 6

Bioassays for Lot Release and Comparability

C. Jane Robinson PhD *Principal Scientist, Biotherapeutics, National Institute for Biological Standards and Control, UK*

1. Introduction
2. Biological activity, potency, functional assays
3. Selection of appropriate bioassay systems
4. Types of functional bioassay system
5. Binding assays
6. Immunoassays
7. Bioassays and unwanted immunogenicity
8. Assay variability, reference standards and relative potency
9. Assay Design

10. Assay precision
11. Surrogate potency assays

Chapter 7

Impact of Formulation Design on Stability and Quality

Patrick Garidel PhD

Stefan Bassarab PhD

Department of Process Science, Formulation Development, Boehringer Ingelheim GmbH, Germany

1. Introduction
2. Stability issues with biologics
3. Liquid versus dry dosage forms
4. Stability testing and quality criteria of drug substance and drug product
5. Conclusions

Chapter 8

Specifications and Drug Substance for Lot Release

Siegfried Schmitt PhD MRSC CChem CSci, *Principal Consultant, Parexel Consulting, UK*

Ralf Hess MSc PhD, *Principal Consultant, Parexel Consulting, Germany*

1. EU and US perspectives on setting specifications
2. Setting the specifications (acceptance criteria) and the action limits (critical product quality attributes) for quality control for specific products
3. How specification requirements tighten during development and how to update the package
4. How design space helps with the determination of specifications, especially for generic products outside the originator product specifications
5. Parametric release, i.e. real-time product release
6. Methodologies that need validation

About the Contributors